Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable.
breast angiosarcoma
multimodality therapy
neoadjuvant chemotherapy
pathologic complete response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
30
06
2021
revised:
24
07
2021
accepted:
27
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
The optimal management of primary angiosarcoma (PAS) and radiation-associated angiosarcoma (RAAS) of the breast remains undefined. Available data show persistently poor survival outcomes following treatment with surgery or chemotherapy alone. The objective of this study was to evaluate long-term outcomes in patients treated with multimodality therapy. Patients diagnosed with stage I-III PAS or RAAS of the breast were identified from our local tumor registry (2010-2020). Patient demographics, tumor characteristics, and treatment were collected. Primary outcomes were local recurrence (LR), distant recurrence (DR), and median overall survival (OS). A secondary outcome was pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC). Mann-Whitney U, chi-squared, or Fisher exact tests were used to analyze data. Kaplan-Meier curves compared OS for PAS and RAAS. Twenty-two patients met inclusion criteria, including 11 (50%) with RAAS and 11 (50%) with PAS. Compared to PAS patients, RAAS patients were older and had more comorbidities. For RAAS patients, median time from radiation to diagnosis was 6 years (IQR: 5-11). RAAS patients were more likely to have a pCR to NAC (40% vs. 20%, Long-term survival can be achieved in patients with PAS and RAAS who undergo multimodality treatment. NAC can result in pCR. The long-term clinical implications of pCR warrant further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
The optimal management of primary angiosarcoma (PAS) and radiation-associated angiosarcoma (RAAS) of the breast remains undefined. Available data show persistently poor survival outcomes following treatment with surgery or chemotherapy alone. The objective of this study was to evaluate long-term outcomes in patients treated with multimodality therapy.
METHODS
METHODS
Patients diagnosed with stage I-III PAS or RAAS of the breast were identified from our local tumor registry (2010-2020). Patient demographics, tumor characteristics, and treatment were collected. Primary outcomes were local recurrence (LR), distant recurrence (DR), and median overall survival (OS). A secondary outcome was pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC). Mann-Whitney U, chi-squared, or Fisher exact tests were used to analyze data. Kaplan-Meier curves compared OS for PAS and RAAS.
RESULTS
RESULTS
Twenty-two patients met inclusion criteria, including 11 (50%) with RAAS and 11 (50%) with PAS. Compared to PAS patients, RAAS patients were older and had more comorbidities. For RAAS patients, median time from radiation to diagnosis was 6 years (IQR: 5-11). RAAS patients were more likely to have a pCR to NAC (40% vs. 20%,
DISCUSSION
CONCLUSIONS
Long-term survival can be achieved in patients with PAS and RAAS who undergo multimodality treatment. NAC can result in pCR. The long-term clinical implications of pCR warrant further investigation.
Identifiants
pubmed: 34359716
pii: cancers13153814
doi: 10.3390/cancers13153814
pmc: PMC8345179
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : T32CA211034
Pays : United States
Organisme : NCI NIH HHS
ID : K12CA226330
Pays : United States
Références
Breast Care (Basel). 2013 Mar;8(1):74-6
pubmed: 24715848
Cureus. 2020 Jun 12;12(6):e8589
pubmed: 32676230
Eur J Surg Oncol. 2021 Aug;47(8):2166-2172
pubmed: 33676792
Breast Cancer Res Treat. 2019 Jun;175(2):409-418
pubmed: 30820717
Breast. 2019 Jun;45:56-60
pubmed: 30877870
Cancer. 2007 Jul 1;110(1):173-8
pubmed: 17541936
BMC Cancer. 2017 Apr 27;17(1):295
pubmed: 28449661
Surg Case Rep. 2018 Nov 7;4(1):131
pubmed: 30406473
Curr Treat Options Oncol. 2018 Mar 8;19(3):14
pubmed: 29520447
J Med Life. 2014 Sep 15;7(3):415-20
pubmed: 25408768
J Clin Oncol. 2015 Sep 1;33(25):2797-802
pubmed: 26215950
Cancers (Basel). 2020 Aug 12;12(8):
pubmed: 32806524
Eur J Cancer. 2014 Jul;50(10):1779-1788
pubmed: 24731859
Int J Surg Case Rep. 2015;13:30-2
pubmed: 26092711
Ann Surg Oncol. 2021 Sep;28(9):5112-5118
pubmed: 33604827
BMC Cancer. 2014 Nov 06;14:816
pubmed: 25376382
J Clin Oncol. 2008 Nov 10;26(32):5269-74
pubmed: 18809609
Ann Surg Oncol. 2012 Aug;19(8):2700-6
pubmed: 22466664
Breast Cancer Res Treat. 2019 Dec;178(3):523-533
pubmed: 31522347
J Immunother Cancer. 2019 Nov 6;7(1):285
pubmed: 31694703
J Immunother Cancer. 2019 Aug 8;7(1):213
pubmed: 31395100
Cureus. 2017 Jun 28;9(6):e1406
pubmed: 30944783
Cancer. 1982 Nov 15;50(10):2000-3
pubmed: 6889910
Breast J. 2012 May-Jun;18(3):276-8
pubmed: 22487313
Am J Clin Oncol. 2016 Oct;39(5):463-7
pubmed: 25521258
Nat Med. 2020 Feb;26(2):181-187
pubmed: 32042194
Radiol Bras. 2018 Sep-Oct;51(5):281-286
pubmed: 30369653
J Surg Oncol. 2015 Jun;111(7):829-33
pubmed: 25772798
Genome Med. 2020 Jul 9;12(1):61
pubmed: 32646514
Oncotarget. 2015 Nov 3;6(34):36041-52
pubmed: 26440310
Curr Opin Oncol. 2018 Mar;30(2):107-112
pubmed: 29194075
J Surg Oncol. 2017 Dec;116(8):1056-1061
pubmed: 29205355
Am J Prev Med. 2019 Jan;56(1):100-108
pubmed: 30573138
Am J Cancer Res. 2019 Nov 01;9(11):2303-2313
pubmed: 31815036